Optimal duration of percutaneous microballoon compression for treatment of trigeminal nerve injury.

Neural Regen Res

Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning Province, China.

Published: January 2014

Percutaneous microballoon compression of the trigeminal ganglion is a brand new operative technique for the treatment of trigeminal neuralgia. However, it is unclear how the procedure mediates pain relief, and there are no standardized criteria, such as compression pressure, compression time or balloon shape, for the procedure. In this study, percutaneous microballoon compression was performed on the rabbit trigeminal ganglion at a mean inflation pressure of 1,005 ± 150 mmHg for 2 or 5 minutes. At 1, 7 and 14 days after percutaneous microballoon compression, the large-diameter myelinated nerves displayed axonal swelling, rupture and demyelination under the electron microscope. Fragmentation of myelin and formation of digestion chambers were more evident after 5 minutes of compression. Image analyzer results showed that the diameter of trigeminal ganglion cells remained unaltered after compression. These experimental findings indicate that a 2-minute period of compression can suppress pain transduction. Immunohistochemical staining revealed that vascular endothelial growth factor expression in the ganglion cells and axons was significantly increased 7 days after trigeminal ganglion compression, however, the changes were similar after 2-minute compression and 5-minute compression. The upregulated expression of vascular endothelial growth factor in the ganglion cells after percutaneous microballoon compression can promote the repair of the injured nerve. These findings suggest that long-term compression is ideal for patients with recurrent trigeminal neuralgia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146163PMC
http://dx.doi.org/10.4103/1673-5374.125347DOI Listing

Publication Analysis

Top Keywords

percutaneous microballoon
20
microballoon compression
20
trigeminal ganglion
16
compression
14
ganglion cells
12
treatment trigeminal
8
trigeminal neuralgia
8
vascular endothelial
8
endothelial growth
8
growth factor
8

Similar Publications

Background: Primary trigeminal neuralgia (PTN) is a type of chronic neuropathic pain disorder caused by neurovascular compression. Percutaneous balloon compression (PBC) is a widely used method for the treatment of PTN.

Objectives: To examine the correlation of balloon pressure (BP) during percutaneous microballoon compression (PBC) with postoperative pain relief and complications in the treatment of primary trigeminal neuralgia (PTN).

View Article and Find Full Text PDF

Objective: To investigate the clinical efficacy of percutaneous microballoon compression in the treatment of recurrent TN.

Methods: This retrospective study included 33 patients who underwent percutaneous microballoon compression for the treatment of recurrent TN from March 2019 to May 2022. Postoperative pain recurrence and facial numbness were assessed according to the Barrow Neurological Institute (BNI) pain score.

View Article and Find Full Text PDF

Background: Factors influencing recurrence after V3 trigeminal nerve surgery remain unknown.

Objectives: To analyze the risk factors affecting recurrence after trigeminal nerve branch V3 surgery, construct a nomogram prediction model, and verify the predictive efficacy of the model.

Study Design: A retrospective study.

View Article and Find Full Text PDF

We describe a case of a 65-year-old woman affected by hemangiopericytoma/solitary fibrous tumor of the right shoulder-subclavian region. Hemangiopericytoma/solitary fibrous tumor is a rare tumor of uncertain malignancy. She reports shoulder pain and inability to abduct the arm and elevate the shoulder.

View Article and Find Full Text PDF

Endovascular therapy is an important method of treating high-flow arteriovenous malformations (AVMs). The nidus of AVMs can be treated by transarterial or percutaneous approaches with the use of ethanol as a strong embolic agent; however, treatment outcomes are not always satisfactory and complications including skin necrosis often occur, particularly following the treatment of superficial lesions. Herein, we describe successful transvenous sclerotherapy of high-flow AVMs in the finger of a 47-year-old female patient that were causing erythema and spontaneous pain using ethanolamine oleate (EO) as a safe sclerosant.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!